Ameriprise Financial Inc. Purchases 65,231 Shares of Sanofi $SNY

Key Points

• Ameriprise Financial Inc. increased its stake in Sanofi by 8.0%, acquiring an additional 65,231 shares, bringing its total to 875,833 shares worth approximately $48.57 million.
• The stock currently holds an average rating of "Buy" from analysts, with a price target of $62.00 following a series of positive upgrades from institutions like JPMorgan Chase & Co. and Barclays.
• Sanofi reported a net margin of 21.47% in its last earnings, although it missed earnings per share estimates, delivering $0.90 EPS compared to the expected $0.96.

Ameriprise Financial Inc. increased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 875,833 shares of the company's stock after acquiring an additional 65,231 shares during the period. Ameriprise Financial Inc.'s holdings in Sanofi were worth $48,573,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its stake in Sanofi by 1.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company's stock worth $612,106,000 after purchasing an additional 193,196 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its position in Sanofi by 1.4% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 24,471 shares of the company's stock worth $1,357,000 after buying an additional 348 shares in the last quarter. Capital Analysts LLC grew its holdings in Sanofi by 14.0% during the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock worth $92,000 after acquiring an additional 204 shares during the last quarter. Legacy Financial Advisors Inc. bought a new stake in Sanofi during the 1st quarter worth about $285,000. Finally, Aviso Financial Inc. increased its position in Sanofi by 3.3% in the 1st quarter. Aviso Financial Inc. now owns 43,197 shares of the company's stock valued at $2,396,000 after acquiring an additional 1,360 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sanofi in a report on Tuesday, August 5th. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Finally, Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $62.00.

Sanofi Stock Performance

SNY stock opened at $50.11 on Thursday. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The company has a market cap of $123.05 billion, a P/E ratio of 12.05, a price-to-earnings-growth ratio of 1.20 and a beta of 0.48. The business's fifty day moving average is $48.73 and its 200-day moving average is $51.66.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the company posted $1.73 EPS. The company's revenue for the quarter was down 7.0% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.